Active Ingredient History

  • Now
Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.   NCATS

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)


$13.2189 - $52.8755
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

14-hydroxydaunomycin | 14-hydroxydaunorubicine | (1s,3s)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside | 2b3-101 | (8s-cis)-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione | adriamycin | adriamycin pfs | adriamycin rdf | adriblastin | adriblastina | ati-0918 | caelyx | doxil | doxirubicin | doxorubicin | doxorubicine | doxorubicin hcl | doxorubicin hydrochloride | doxorubicin hydrochloride liposome | doxorubicin liposomal | doxorubicin pegylated | doxorubicinum | dox-sl | glutathione pegylated liposomal doxorubicin | hydroxydaunomycin | hydroxydaunorubicin | hydroxydaunorubicin hcl | hydroxydaunorubicin hydrochloride | lipodox | liposomal doxorubicin | liposomal pegylated doxorubicin | myocet | pegylated doxorubicin | pegylated liposomal doxorubicin | rubex | rubidox | tlc d-99


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue